GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Strong cash flow and growth will enable GlaxoSmithKline's consumer products business to cope with a higher debt load after its planned separation next year, the division's head of marketing told Reuters.

GSK consumer arm confident that growth, cash flow will help with debt

Having lagged behind on COVID-19, GlaxoSmithKline has recently made headlines with progress on its collaborations with Vir and Sanofi. The planned spin-off next year will likely necessitate a dividend cut for the sake of sustainability.

COVID-19 Treatments, Spin-Offs Make GlaxoSmithKline A Value Stock

GlaxoSmithKline Plc (NYSE: GSK) appeared to dodge a potential shakeup last week when Elliott Management said it would not push the sale of its vaccines and pharmaceuticals business or push to slash R&D spending. But now, the activist firm is reportedly raising questions about the company's CEO Emma Walmsley.

Activist Hedge Fund Elliott Questions GSK CEO Walmsley's Leadership: Mail on Sunday

AstraZeneca

These pharmaceutical companies might make great long-term additions to your portfolio.

2 Deeply Discounted Dividend Stocks to Buy and Hold Right Now

The Times of London reports that activist investor Paul Singer's hedge fund Elliott Management will not push the sale of GlaxoSmithKline Plc's (NYSE: GSK) vaccines and pharmaceuticals business. Also, Elliott is not planning to push for cuts to Glaxo's £5 billion research and development budget and will support GSK remaining in the U.K.

Activist Hedge Fund Elliott Management Backs Away from Forced GlaxoSmithKline's Vaccines, Pharma Business Sale: The Times

Vir Biotechnology

There are now three antibody-based treatments available in the U.S. to treat adults and teens with mild or moderate forms of COVID-19, though all require intravenous infusions and are not the kind of medications that can be picked up at a local pharmacy.

The FDA authorized the third monoclonal antibody treatment. Here's why Vir and GSK say the U.S. still needs COVID-19 therapies

GlaxoSmithKline and Vir Biotechnology won FDA authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. The post The Surprising Move Vir Stock Made After Winning Covid Drug Authorization appeared first on Investor's Business Daily.

The Surprising Move Vir Stock Made After Winning Covid Drug Authorization

GSK shareholders have reasons to be skeptical about CEO Emma Walmsley's record, with the value of the stock down 16% since she took over four years ago.

Activist Fund Elliott Management Could Give GSK Some Space: Report

Sanofi

Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study

Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.

Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod

The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline Plc (NYSE: GSK) for treating mild-to-moderate COVID-19 in people aged 12 years and older. The EUA comes after Vir's antibody proved 85% effective at preventing hospitalization in high-risk, newly diagnosed COVID-19 patients.

Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug

GlaxoSmithKline plc and Vir Biotechnology Inc. said the U.S. Food and Drug Administration has granted emergency use authorization to its single-dose monoclonal antibody treatment sotrovimab in mild-to-moderate COVID-19 in adults and pediatric patients who are at high risk of severe illness, including hospitalization or death. Vir Chief Executive George Scangos said an interim analysis of data produced in a laboratory found the antibody treatment showed an 85% reduction in all-cause hospitalizations or death and is effective against all known variants of concern, including the emerging variant from India.

GlaxoSmithKline and Vir win FDA emergency authorization for COVID antibody treatment in adults and children

French pharmaceutical group Sanofi [s:fr: san] and U.K. drug company GlaxoSmithKline said they have begun global Phase 3 efficacy studies of their jointly produced COVID-19 candidate. The randomized, double-blind placebo controlled study will involve more than 35,000 volunteers aged 18 and older from the U.S., Africa, Asia and Latin America.

Sanofi and GlaxoSmithKline begin Phase 3 study of COVID-19 vaccine candidate

One part of the trial will test the vaccine against the South African variant of the virus.

New Covid-19 Vaccine Will Be Produced This Year As Sanofi, GSK Launch Phase 3 Trial

Production of the coronavirus vaccine developed by French firm Sanofi and GlaxoSmithKline (GSK) will begin within weeks, the firms have said.

Another COVID vaccine set to enter production within weeks - and UK has 60m doses ordered

GlaxoSmithKline PLC (LON:GSK) and Vir Biotechnology, Inc. (NASDAQ:VIR) have announced the US Food and Drug Administration (FDA) granted emergency use authorisation for their COVID-19 treatment. Sotrovimab will be used to help adults and paediatric patients aged over 12 with mild-to-moderate symptoms, and who are at high risk for progression to severe COVID-19, including hospitalisation or death.

GlaxoSmithKline receives US emergency authorisation for COVID-19 treatment

Sanofi and GSK initiate global Phase 3 clin i cal efficacy study of COVID-19 vaccine candidate

Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

Amazon

Alibaba

Bayer AG

British American Tobacco

Anheuser-Busch InBev

Salesforce

Dominion Energy

Enbridge

Imperial Brands PLC

Kellogg

Lockheed Martin

Merck

ServiceNow

Polaris

Philip Morris

Roche Holding AG

Tencent Holdings Limited

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating).

Wide-Moat Stocks On Sale - The June 2021 Heat Map

The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.

Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod

GlaxoSmithKline PLC ( GSK , Financial) is shoring up its defenses as the giant British pharmaceutical company girds for a potential battle with a well-known activist investor. Fierce Pharma reported embattled CEO Emma Walmsley has enlisted the support of three large institutional investors in the company's proxy fight against Elliott Management.

GlaxoSmithKline Gains Key Supporters in Potential Proxy Battle

The European Medicines Agency's advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) antibody COVID-19 treatment, sotrovimab, can be used. The opinion covers confirmed COVID-19 in adults and adolescents who don't require supplemental oxygen therapy and are at risk of progressing to severe COVID-19.

GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion

Lumen Technologies

Here we give some of our picks that we think can weather inflation effectively, without being part of the recent commodity run-up.

Stealth Buys For Inflationary Times

Innoviva

GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392 million, at a 3% discount or $12.25 per share. Innoviva, a royalty management company that collaborates with GSK on respiratory treatments, including Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta, has counted GSK among its investors for years.

GSK Exits Respiratory Partner Innoviva In $392M Deal

These are two cheap stocks in an overvalued market.

Better Buy for 2021: GlaxoSmithKline or Sanofi?

Trial participants have 10 times more antibodies in their systems than patients recovering from COVID-19.

A plant-based vaccine from a GlaxoSmithKline alliance with Medicago shows strong antibody response

News for GlaxoSmithKline Stock (GSK)